Cell Genesys Inc. (CEGE) Sees Positive Cancer Test Results; Shares Jump 4%
Cell Genesys Inc. (CEGE) said Friday its GVAX immunotherapy treatment for recurrent prostate cancer did well in early stage clinical tests. Shares of the San Francisco, Calif.-based company were up nearly 4% to a high of $3.25 during late-day trading. Data from the trial, which enrolled 19 patients, indicate that GVAX helped 79% of the patients boost antibodies. In addition, the drug was generally well tolerated, with the most common side effects being injection-site reactions in most patients and mild flu-like symptoms in some patients, according to Cell Genesys. “We are now planning a larger randomized trial to further examine…